337 related articles for article (PubMed ID: 34484871)
1. Avelumab internalization by human circulating immune cells is mediated by both Fc gamma receptor and PD-L1 binding.
Jin H; D'Urso V; Neuteboom B; McKenna SD; Schweickhardt R; Gross AW; Fomekong Nanfack Y; Paoletti A; Carter C; Toleikis L; Fluck M; Scheuenpflug J; Cai T
Oncoimmunology; 2021; 10(1):1958590. PubMed ID: 34484871
[TBL] [Abstract][Full Text] [Related]
2. Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacy.
Cohen Saban N; Yalin A; Landsberger T; Salomon R; Alva A; Feferman T; Amit I; Dahan R
Sci Immunol; 2023 Mar; 8(81):eadd8005. PubMed ID: 36867679
[TBL] [Abstract][Full Text] [Related]
3. Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis.
Grenga I; Donahue RN; Gargulak ML; Lepone LM; Roselli M; Bilusic M; Schlom J
Urol Oncol; 2018 Mar; 36(3):93.e1-93.e11. PubMed ID: 29103968
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma.
Gaiser MR; Bongiorno M; Brownell I
Expert Rev Clin Pharmacol; 2018 Apr; 11(4):345-359. PubMed ID: 29478343
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Avelumab Maintenance Therapy Plus Best Supportive Care vs. Best Supportive Care Alone for Advanced or Metastatic Urothelial Carcinoma.
Xie Q; Zheng H; Chen Y; Peng X
Front Public Health; 2022; 10():837854. PubMed ID: 35570929
[TBL] [Abstract][Full Text] [Related]
6. Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma.
Faiena I; Cummings AL; Crosetti AM; Pantuck AJ; Chamie K; Drakaki A
Drug Des Devel Ther; 2018; 12():209-215. PubMed ID: 29416316
[TBL] [Abstract][Full Text] [Related]
7. Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.
Boyerinas B; Jochems C; Fantini M; Heery CR; Gulley JL; Tsang KY; Schlom J
Cancer Immunol Res; 2015 Oct; 3(10):1148-1157. PubMed ID: 26014098
[TBL] [Abstract][Full Text] [Related]
8. Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody.
Donahue RN; Lepone LM; Grenga I; Jochems C; Fantini M; Madan RA; Heery CR; Gulley JL; Schlom J
J Immunother Cancer; 2017; 5():20. PubMed ID: 28239472
[TBL] [Abstract][Full Text] [Related]
9. FcγR interaction is not required for effective anti-PD-L1 immunotherapy but can add additional benefit depending on the tumor model.
Sow HS; Benonisson H; Breukel C; Visser R; Verhagen OJHM; Bentlage AEH; Brouwers C; Claassens JWC; Linssen MM; Camps M; van Hall T; Ossendorp F; Fransen MF; Vidarsson G; Verbeek JS
Int J Cancer; 2019 Jan; 144(2):345-354. PubMed ID: 30259976
[TBL] [Abstract][Full Text] [Related]
10. Model-informed drug development supporting the approval of the avelumab flat-dose regimen in patients with advanced renal cell carcinoma.
Masters JC; Khandelwal A; di Pietro A; Dai H; Brar S
CPT Pharmacometrics Syst Pharmacol; 2022 Apr; 11(4):458-468. PubMed ID: 35166465
[TBL] [Abstract][Full Text] [Related]
11. Avelumab for the treatment of urothelial cancer.
Rodriguez-Vida A; Bellmunt J
Expert Rev Anticancer Ther; 2018 May; 18(5):421-429. PubMed ID: 29540084
[TBL] [Abstract][Full Text] [Related]
12. Avelumab: search for combinations of immune checkpoint inhibition with chemotherapy.
Hamilton G
Expert Opin Biol Ther; 2021 Mar; 21(3):311-322. PubMed ID: 32954871
[TBL] [Abstract][Full Text] [Related]
13. Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis.
Apolo AB; Ellerton JA; Infante JR; Agrawal M; Gordon MS; Aljumaily R; Gourdin T; Dirix L; Lee KW; Taylor MH; Schöffski P; Wang D; Ravaud A; Manitz J; Pennock G; Ruisi M; Gulley JL; Patel MR
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037118
[TBL] [Abstract][Full Text] [Related]
14. Durvalumab for the treatment of urothelial carcinoma.
Alsharedi M; Srivastava R; Elmsherghi N
Drugs Today (Barc); 2017 Dec; 53(12):647-652. PubMed ID: 29517083
[TBL] [Abstract][Full Text] [Related]
15. Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab.
Fujii R; Friedman ER; Richards J; Tsang KY; Heery CR; Schlom J; Hodge JW
Oncotarget; 2016 Jun; 7(23):33498-511. PubMed ID: 27172898
[TBL] [Abstract][Full Text] [Related]
16. Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer.
Bourhis J; Stein A; Paul de Boer J; Van Den Eynde M; Gold KA; Stintzing S; Becker JC; Moran M; Schroeder A; Pennock G; Salmio S; Esser R; Ciardiello F
Cancer Treat Rev; 2021 Jun; 97():102172. PubMed ID: 33989949
[TBL] [Abstract][Full Text] [Related]
17. The Emerging Role of PD-1/PD-L1-Targeting Immunotherapy in the Treatment of Metastatic Urothelial Carcinoma.
Gwynn ME; DeRemer DL
Ann Pharmacother; 2018 Jan; 52(1):60-68. PubMed ID: 28831813
[TBL] [Abstract][Full Text] [Related]
18. Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity.
Hamilton G; Rath B
Expert Opin Biol Ther; 2017 Apr; 17(4):515-523. PubMed ID: 28274143
[TBL] [Abstract][Full Text] [Related]
19. Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab.
Jagoda EM; Vasalatiy O; Basuli F; Opina ACL; Williams MR; Wong K; Lane KC; Adler S; Ton AT; Szajek LP; Xu B; Butcher D; Edmondson EF; Swenson RE; Greiner J; Gulley J; Eary J; Choyke PL
Mol Imaging; 2019; 18():1536012119829986. PubMed ID: 31044647
[TBL] [Abstract][Full Text] [Related]
20. Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody.
Nagaya T; Nakamura Y; Sato K; Harada T; Choyke PL; Hodge JW; Schlom J; Kobayashi H
Oncotarget; 2017 Jan; 8(5):8807-8817. PubMed ID: 27716622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
